Using a vaccine to enhance CAR T cell therapy for B-cell lymphoma
Official title: CMV-specific CD19 CAR T cells amplified in vivo using CMV Triplex vaccine for B-NHL
Funded at Beckman Research Institute/city of Hope · NIH-11028168 · Data updated 2026-11-12
This study is testing a new way to boost CAR T cell therapy for people with aggressive B-cell Non-Hodgkin's Lymphoma by using a special vaccine to help T cells better fight the cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $738,698 |
| NIH project number | 1R01CA296280-01 |
| Project ID | NIH-11028168 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over 21 years old who have aggressive B-cell Non-Hodgkin's Lymphoma and have not responded well to standard treatments.
✕Less likely to help
Patients with other types of cancer or those who have not been diagnosed with B-cell Non-Hodgkin's Lymphoma may not benefit from this research.
What this research studies
This research investigates a new method to improve CAR T cell therapy for patients with aggressive B-cell Non-Hodgkin's Lymphoma (B-NHL). It focuses on selecting and amplifying CMV-specific T cells using a novel vaccine called Triplex, which has shown promising safety and immune response in previous trials. The modified T cells will be infused into patients to enhance their ability to target and kill lymphoma cells. This approach aims to overcome the limitations of current CAR T cell therapies, which often struggle with persistence and effectiveness.
Why it matters
Potential benefit: If successful, this research could lead to more effective and durable treatments for patients with B-NHL, potentially improving their chances of long-term remission.
How similar studies have gone: Previous clinical trials using the Triplex vaccine have shown promising results in enhancing immune responses, indicating potential success for this novel approach.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Wang, Xiuli — Beckman Research Institute/city of Hope
- Study coordinator: Wang, Xiuli
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.